Stem Cell Collaboration and Licensing Deals 2010-2024
Stem Cell Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2024
Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of stem cell deals from 2010 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter stem cell deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 530 stem cell deals announced since 2010 including financial terms where available including links to online deal records of actual stem cell partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of stem cell dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in stem cell dealmaking since 2010.
Chapter 3 provides an overview of the leading stem cell deals since 2010. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of stem cell deals signed and announced since Jan 2010, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2010.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Stem Cell Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2010
• Browse stem cell collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
Stem Cell Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of stem cell trends and structure of deals entered into by leading biopharma companies worldwide.
Stem Cell Collaboration and Licensing Deals includes:
• Trends in stem cell dealmaking in the biopharma industry
• Directory of stem cell deal records covering pharmaceutical and biotechnology
• The leading stem cell deals by value
• Most active stem cell licensing dealmakers
Stem Cell Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Stem Cell Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2010
• Browse stem cell collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in stem cell dealmaking
2.1. Introduction
2.2. Stem cell deals over the years
2.3. Most active stem cell dealmakers
2.4. Stem cell deals by deal type
2.5. Stem cell deals by therapy area
2.6. Stem cell deals by industry sector
2.7. Deal terms for stem cell deals
2.7.1 Stem cell deals headline values
2.7.2 Stem cell deal upfront payments
2.7.3 Stem cell deal milestone payments
2.7.4 Stem cell royalty rates
Chapter 3 – Leading stem cell deals
3.1. Introduction
3.2. Top stem cell deals by value
Chapter 4 – Most active stem cell dealmakers
4.1. Introduction
4.2. Most active stem cell dealmakers
4.3. Most active stem cell deals company profiles
Chapter 5 – Stem cell contracts dealmaking directory
5.1. Introduction
5.2. Stem cell contracts dealmaking directory
Chapter 6 – Stem cell dealmaking by technology type
Deal directory
Deal directory – Stem cell deals by company A-Z
Deal directory – Stem cell deals by deal type
Deal directory – Stem cell deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Stem cell deals since 2010
Figure 2: Active stem cell dealmaking activity – 2010 - 2024
Figure 3: Stem cell deals by deal type since 2010
Figure 4: Stem cell deals by therapy area since 2010
Figure 5: Stem cell deals by industry sector since 2010
Figure 6: Stem cell deals with a headline value
Figure 7: Stem cell deals with an upfront value
Figure 8: Stem cell deals with a milestone value
Figure 9: Stem cell deals with a royalty rate value
Figure 10: Top stem cell deals by value since 2010
Figure 11: Most active stem cell dealmakers 2010 - 2024
Figure 12: Stem cell deals by technology type since 2010
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted PDF)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, Abu Dhabi Stem Cells Center, Accellta, Actinium Pharmaceuticals, AGC Asahi Glass, Ageless Biotech, AgeX Therapeutics, AiVita Biomedical, Akadeum Life Sciences, Alkem Laboratories, Allele Biotechnology and Pharmaceuticals, American Society of Hematology, American Type Culture Collection (ATCC), Amgen, Angiostem, Anthony Nolan, Apceth, Arbor Biotechnologies, Ascendance Biotechnology, Astellas Pharma, AstraZeneca, Athersys, Australian Research Council, Axcelead Drug Discovery Partners, Axiogenesis, AxoSim, Barbara Ann Karmanos Cancer Institute, Be The Match BioTherapies, Bio-Techne, BioCardia, BioEclipse Therapeutics, BiolineRX, Biological Industries, Biomed, bioRASI, BlueRock Therapeutics, Boehringer Ingelheim, Bone Therapeutics, BrainStorm Cell Therapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Calidi Biotherapeutics, California Institute for Regenerative Medicine, Calimmune, Cell2in, Cell Care Therapeutics, Cellect Biotechnology, Cellectricon, Celling Biosciences, CellProThera, Celltex Therapeutics, Cellular Biomedicine, Cellular Dynamics International, Censo Biotechnologies, Centogene, Centre for Drug Research and Development (CDRD), Children's Hospital Boston, China Southeast University, Cincinnati Children’s Hospital Medical Center, Cipla, Citius Pharmaceuticals, Cognate BioServices, Columbia University, Creative Medical Technologies, CRISPR Therapeutics, Crown Bioscience, Cynata Therapeutics, CytoMed Therapeutics, CYTOVIA Therapeutics, Deepcell, DefiniGEN, Department of Defense, DePuy, EdiGene, Elixirgen, ERS Genomics, Eterna Therapeutics, Ethos Discovery, Eutilogics, Evotec, ExCellThera, Exploit Technologies, Florica Therapeutics, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Fraunhofer Institute for Molecular Ecology (IME), Fujifilm, FUJIFILM Cellular Dynamics, Gallant Therapeutics, Gamida Cell, GE Healthcare, Genezen, Golden Meditech, GSK, Hadassah Medical Center, Haihe Laboratory of Cell Ecosystem, Hamad Bin Khalifa University, Harvard Stem Cell Institute, Harvard University, Healios K.K., Heartseed, Hemostemix, Histogen, Hong Kong Baptist University, Huapont Pharma, Human Life CORD Japan, Immunis, ImmunityBio, ImmunoCellular Therapeutics, Implant Therapeutics, Indiana University, Insitro, Instem, Institute Of Molecular Biotechnology, InVivo Therapeutics, Israeli National Authority for Technological Innovation, Jadi Cell, Janssen Biotech, Jasper Therapeutics, JCR Pharmaceuticals, Johns Hopkins University, Johnson & Johnson Innovation, Keck School of Medicine of USC, Kings College London, Kite Pharma, Kumamoto University, Kyoto University, Leiden University, Leona M and Harry B Helmsley Charitable Trust, Lineage Cell Therapeutics, Longeveron, Lupus Foundation of America (LFA), Macquarie University, Magenta Therapeutics, Maryland Stem Cell Research Fund, Maryland Technology Development Corporation, Maxcyte, McGill University, Medac, Medexus Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Merck and Co, Mesoblast, Metrion Biosciences, Michael J Fox Foundation, Molecular Templates, Multiclonal Therapeutics, Murdoch Childrens Research Institute, myTomorrows, NanoCellect Biomedica, Nano Dimension, NantKwest, Nanyang Technological University, National Cancer Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute on Aging, National Institutes of Health, National Science Foundation, National University of Ireland, Galway (NUI Galway), Ncardia, Northwestern University, Novellus Therapeutics, Novo Nordisk, Nvidia, Ocumension Therapeutics, Omeros, OncoImmune, Orchard Therapeutics, Organovo, ORIG3N, Orthocell, Pathways to Stem Cell Science, Plasticell, Platelet BioGenesis, Pluristem Therapeutics, Pluristyx, PreCerv, Procella Therapeutics, Procyon Technologies, Pulthera, Q Therapeutics, Regeneus, ReNeuron, Renovacare, Research Products Development Company, Royal Children’s Hospital, Rubedo Life Sciences, RxBio, Salk Institute, Sana Biotechnology, SanBio, Scaled Biolabs, SCM Pharma, Seattle Childrens Research Institute, Seres Therapeutics, Shanghai Cell Therapy Group, Sharp Edge Labs, Shoreline Biosciences, SimonMed Imaging, Sirion Biotech, Smartwise, Spinogenix, Stanford University, StemCardia, Stemcell Technologies, Stemedica Cell Technologies, Stem Genomics, Stempeutics, TaiRx, Takeda Pharmaceutical, Technology University Dresden, Teijin, Terumo Blood and Cell Technologies, The New York Stem Cell Foundation, Therakine, Therapeutic Solutions International, The Regents of the University of California, Thrive Bioscience, TiGenix, Tissue Genesis, TONIX Pharmaceuticals, Trestle Biotherapeutics, Trillium Therapeutics, Tu Dresden, U CAN-CER VIVE Foundation, University Ann & Robert H. Lurie Children’s Hospital, University Health Network, University of Adelaide, University of California, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Maryland, University of Pittsburgh, University of Queensland, University of Southern California, University of Tokyo, University of Washington, Vascugen, Vertex Pharmaceuticals, ViaCyte, VistaGen Therapeutics, Vivo Biosciences, Vor Biopharma, WCTE, W L Gore, Yumanity Therapeutics
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
